France's Valneva misses 2025 revenue expectations, forecasts lower product sales in 2026

Valneva SE

19/02/2026 06:11

Overview

France-based vaccine maker's 2025 revenue missed analyst expectations

Company reported strong year-end cash position of €109.7 mln

CEO's contract renewed for three more years, ensuring leadership continuity

Outlook

Valneva expects 2026 total revenues between €155-170 mln

Company anticipates Phase 3 Lyme disease vaccine data in first half of 2026

Valneva forecasts lower product sales in 2026 due to wind-down of third-party sales

Result Drivers

PRODUCT SALES DECLINE - Product sales decreased by 3.3% due to a 42.3% drop in third-party sales, as expected

CASH POSITION - Strong year-end cash position of €109.7 million, supported by successful debt refinancing

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Miss
EUR 157.90 mln
EUR 170.63 mln (6 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Valneva SE is €7.70, about 66.4% above its February 18 closing price of €4.63

Press Release: ID:nGNE2VHTn8

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)